TY - JOUR
T1 - Metabolic alterations in patients who develop Traumatic Brain Injury (TBI)-induced hypopituitarism.
AU - PRODAM, Flavia
AU - Gasco, V
AU - CAPUTO, Marina
AU - ZAVATTARO, Marco
AU - Pagano, L
AU - MARZULLO, Paolo
AU - Belcastro, S
AU - Busti, A
AU - MT, Samà
AU - Perino, C
AU - Grottoli, S
AU - Ghigo, E
AU - AIMARETTI, Gianluca
N1 - Funding Information:
This study was supported by Regione Piemonte (grant no. 2827, 2008 ), and University of Eastern Piedmont, Ministero dell'Università e della Ricerca Scientifica (grant no. 20082P8CCE , 2008).
PY - 2013
Y1 - 2013
N2 - Hypopituitarism is associated with metabolic alterations but in TBIinduced hypopituitarism data are scanty. The aim of our study was to evaluate the prevalence of naïve hypertension, dyslipidemia, altered glucose metabolism in TBIinduced
hypopituitarism patients.
Design. Cross-sectional retrospective study in a tertiary care endocrinology center. 54 adult patients encountering a moderate or severe TBI were evaluated in the chronic phase (at least 12 months after injury) after-trauma. Presence of hypopituitarism,
BMI, hypertension, fasting blood glucose and insulin levels, oral glucose tolerance test (if available) and a lipid profile were evaluated.
Results. The 27.8% of patients showed various degrees of hypopituitarism. In particular, 9.3% had total, 7.4% multiple and 11.1% isolated hypopituitarism. GHD was present in 22.2% of patients. BMI was similar between the two groups.
Hypopituitaric patients presented a higher prevalence of dyslipidemia (p<0.01) and altered glucose metabolism (p<0.005) with respect to non hypopituitaric patients. In particular, triglycerides (p<0.05) and HOMA-IR (p<0.02) were higher in
hypopituitaric TBI patients.
Conclusions. We showed that long-lasting TBI patients who develop hypopituitarism frequently present metabolic alterations, in particular altered glucose levels, insulin resistance and hypertriglyceridemia. In view of the risk of premature cardiovascular death in hypopituitaric patients, major attention has to been paid in those who encountered a TBI, because they suffer from the same comorbidities and may present other deterioration factors due to complex pharmacological treatments and restriction in participation in life activities and healthy lifestyle.
AB - Hypopituitarism is associated with metabolic alterations but in TBIinduced hypopituitarism data are scanty. The aim of our study was to evaluate the prevalence of naïve hypertension, dyslipidemia, altered glucose metabolism in TBIinduced
hypopituitarism patients.
Design. Cross-sectional retrospective study in a tertiary care endocrinology center. 54 adult patients encountering a moderate or severe TBI were evaluated in the chronic phase (at least 12 months after injury) after-trauma. Presence of hypopituitarism,
BMI, hypertension, fasting blood glucose and insulin levels, oral glucose tolerance test (if available) and a lipid profile were evaluated.
Results. The 27.8% of patients showed various degrees of hypopituitarism. In particular, 9.3% had total, 7.4% multiple and 11.1% isolated hypopituitarism. GHD was present in 22.2% of patients. BMI was similar between the two groups.
Hypopituitaric patients presented a higher prevalence of dyslipidemia (p<0.01) and altered glucose metabolism (p<0.005) with respect to non hypopituitaric patients. In particular, triglycerides (p<0.05) and HOMA-IR (p<0.02) were higher in
hypopituitaric TBI patients.
Conclusions. We showed that long-lasting TBI patients who develop hypopituitarism frequently present metabolic alterations, in particular altered glucose levels, insulin resistance and hypertriglyceridemia. In view of the risk of premature cardiovascular death in hypopituitaric patients, major attention has to been paid in those who encountered a TBI, because they suffer from the same comorbidities and may present other deterioration factors due to complex pharmacological treatments and restriction in participation in life activities and healthy lifestyle.
UR - https://iris.uniupo.it/handle/11579/35961
U2 - 10.1016/j.ghir.2013.04.001
DO - 10.1016/j.ghir.2013.04.001
M3 - Article
SN - 1096-6374
VL - 23
SP - 109
EP - 113
JO - Growth Hormone and IGF Research
JF - Growth Hormone and IGF Research
IS - 4
ER -